drugset / Trial / NCT00005855
Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1/2
Completed
48 enrolled
New Approaches to Brain Tumor Therapy Consortium
National Cancer Institute (NCI) · collab
Non-randomizedOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of efaproxiral when given with carmustine and to see how well they work in treating patients with progressive or recurrent malignant glioma.
Timeline
- Start
- 2000-07
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | efaproxiral | Small molecule | — | Intravenous |
| Background | carmustine | Small molecule | — | Intravenous |